Altamira Therapeutics Ltd
HAMILTON, BERMUDA , Sept. 13, 2022 (GLOBE NEWSWIRE) —
Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that it has reached its extended enrollment target of 160 confirmed subjects in its COVAMID clinical investigation to evaluate the safety, tolerability, and efficacy of its Bentrio™ nasal spray in patients with acute COVID-19.
Bentrio is an OTC drug-free nasal spray designed for protection against airborne viruses and allergens. It is being marketed in several countries throughout Europe and Asia to help protect against allergic rhinitis and, where approved, against viral infection. Recently, Bentrio was cleared in the US for OTC marketing for the treatment of allergic rhinitis. It is expected to become available in progressively more countries through a growing global network of distributors.
COVAMID is a randomized, placebo controlled clinical trial to evaluate the ability of Bentrio nasal spray to reduce the SARS-CoV-2 viral load in the nose, alleviate COVID-19 signs and symptoms, and decrease the frequency of COVID-19 related hospital admissions. In the COVAMID trial, the COVID-19 patients are randomized at a 2:1:1 ratio to receive for 10 days either Bentrio, a placebo (Bentrio minus its key mineral component), or no treatment, followed by a 10-day observation phase. COVAMID is being conducted in Bulgaria and North Macedonia.
Following a blinded interim analysis, the Company in early August announced that the size of the COVAMID study population would be increased from 136 to 160 patients to ensure adequate statistical power. Altamira expects to announce top-line data from the COVAMID trial during the fourth quarter of 2022.
With a positive outcome from the COVAMID clinical trial, the Company plans to seek an expansion of its product label to also include viral infections in those countries requiring supportive clinical data. So far, Altamira has demonstrated that Bentrio provides effective protection from infection with human rhinovirus (common cold), influenza virus and SARS-CoV-2 in cell cultures with human nasal epithelia cells.
“We are glad to have swiftly completed the additional patient enrollment for COVAMID,” commented Jean Lachance, Head of Altamira’s OTC Consumer Health business unit. “Based on the compelling results which we already achieved with Bentrio in several SARS-CoV-2 assays, we are confident to see the protective effects confirmed also in a clinical setting. We consider Bentrio well-positioned to help protect people in a world with manifold and growing exposures to airborne viruses — for which Covid-19 has dramatically raised consumer awareness.”
Bentrio is an OTC drug-free nasal spray for personal protection against airborne allergens and, where approved, against airborne viruses. Upon application into the nose, Bentrio forms a protective gel layer …….